- Profile
- Personal Information
- Publications
Experts in Cardiology
Prof. Dr. Mohammed Ibrahim Abdel Magued Arunima Sengupta Dr. Naibedya Chattopadhyay David J. Burritt Anthony Emekalam Sunil Baldwa Michael J. Miller Hiroko Beck Vivian M. Abascal David H Adams Susan Zieman Ismayil Ahmet Mingyi Wang ASHEQUL ISLAM Barbara Radziszewska Thomas R. Cimato David M. Zlotnick Ronald Kohanski Gen Suzuki Malcolm McHenry View More"Mr Lan joined the Probiotec board in February 2017. Mr Lan was the founding Managing Director of Sydney-based pharmaceutical company Aspen Pharmacare Australia, a subsidiary of South African listed Aspen Pharmacare Holdings. During Mr Lan's tenure, Aspen Australia experienced exponential growth, particularly after the acquisition of Sigma's branded and generics portfolio in 2011 (as well as its manufacturing facilities), and is today one of Australia's largest pharmaceutical companies, with a diverse portfolio of over 260 products covering prescription and OTC. When Mr Lan retired after 15 years with the company, Aspen's Asia Pacific operations (including Australia) had annualised sales in excess of $1 billion. Prior to joining Aspen, Mr Lan has had extensive experience working in the pharmaceutical industry internationally, including senior roles with Ciba-Geigy (now Novartis) in Switzerland and Saudi Arabia, as well as with Sanofi-Aventis in Australia. Mr Lan holds an MBA from the University of Michigan. " "Mr Lan joined the Probiotec board in February 2017. Mr Lan was the founding Managing Director of Sydney-based pharmaceutical company Aspen Pharmacare Australia, a subsidiary of South African listed Aspen Pharmacare Holdings. During Mr Lan's tenure, Aspen Australia experienced exponential growth, particularly after the acquisition of Sigma's branded and generics portfolio in 2011 (as well as its manufacturing facilities), and is today one of Australia's largest pharmaceutical companies, with a diverse portfolio of over 260 products covering prescription and OTC. When Mr Lan retired after 15 years with the company, Aspen's Asia Pacific operations (including Australia) had annualised sales in excess of $1 billion. Prior to joining Aspen, Mr Lan has had extensive experience working in the pharmaceutical industry internationally, including senior roles with Ciba-Geigy (now Novartis) in Switzerland and Saudi Arabia, as well as with Sanofi-Aventis in Australia. Mr Lan holds an MBA from the University of Michigan. "
pharmaceutical Industry